abcam

## ab134372

# PE Anti-CD41 antibody [MEM-06]

Anti-CD41 antibody [MEM-06] conjugated to PE - suitable for flow cytometry, and reacts with human samples. Clone [MEM-06] is a mouse monoclonal antibody cited in 6 publications.

Design your panel with our interactive flow cytometry panel builder. Click here.

## Key facts

| | |
|---|---|
| **Isotype** | IgG1 |
| **Host species** | Mouse |
| **Conjugation** | PE |
| **Excitation/Emission** | Ex: 480;565nm, Em: 578nm |
| **Storage buffer** | pH: 7.4 Preservative: 0.1% Sodium azide Constituents: PBS, 0.2% BSA |
| **Form** | Liquid |
| **Clonality** | Monoclonal |
| **Immunogen** | Cell preparation containing ITGA2B protein. The exact immunogen used to generate this antibody is proprietary information. Database link P08514 |
| **Clone number** | MEM-06 |
| **Purification technique** | Size-exclusion chromatography |
| **Purification notes** | ab134372 is conjugated with R-Phycoerythrin (PE) under optimum conditions. The reagent is free of unconjugated FITC and adjusted for direct use. |

## Reactivity data

## Flow Cyt

**Tested**

| | |
|---|---|
| **Species** | Human |
| **Dilution info** | 20 µL for $10^6$ Cells |
| **Notes** | Use 20 µl reagent / 100 µl of whole blood or 10^6 cells in a suspension. |

## Target data

See full target information ITGA2B

| | |
|---|---|
| **Function** | Integrin alpha-IIb/beta-3 (ITGA2B:ITGB3) is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. It recognizes the sequence R-G-D in a wide array of ligands. It recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain (By similarity). Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen (PubMed:9111081). This step leads to rapid platelet aggregation which physically plugs ruptured endothelial cell surface (By similarity). Integrin ITGA2B:ITGB3 is also the receptor of erythrocyte-specific ICAM4 ligand involved in heterotypic cell-cell adhesion between erythrocytes and activated platelets (PubMed:12477717). |

## Storage

| | |
|---|---|
| **Shipped at conditions** | Blue Ice |
| **Appropriate short-term storage conditions** | +4°C |
| **Appropriate long-term storage conditions** | +4°C |

## Product promise

**Tested**

We have tested this species and application combination and it works. It is covered by our product promise.

**Expected**

We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.

**Predicted**

This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.

**Not recommended**


We do not recommend this combination. It is not covered by our product promise.

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.


## 2 product images




### Flow Cytometry - PE Anti-CD41 antibody [MEM-06] (ab134372)

CD41 Flow Cytometry staining of Human peripheral blood using mouse Anti-CD41 antibody

Flow cytometry surface staining pattern of human peripheral whole blood stained using ab134372 (20 µl reagent / 100 µl of peripheral whole blood).




### Flow Cytometry - PE Anti-CD41 antibody [MEM-06] (ab134372)

CD41 Flow Cytometry staining of Human peripheral blood using mouse Anti-CD41 antibody

Separation of human CD41 positive CD45 negative thrombocytes (red-filled) from CD41 negative lymphocytes (black-dashed) in flow cytometry analysis (surface staining) of human peripheral whole blood stained using ab134372 (20 µl reagent / 100 µl of peripheral whole blood).

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.